$477 Million is the total value of Abingworth LLP's 17 reported holdings in Q3 2020. The portfolio turnover from Q2 2020 to Q3 2020 was 18.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PCVX | Vaxcyte | $205,851,000 | +56.5% | 4,168,718 | 0.0% | 44.03% | +19.7% | |
| PSNL | Sell | Personalis | $96,701,000 | +36.9% | 4,462,452 | -18.1% | 20.68% | +4.8% |
| PHAT | Phathom | $44,516,000 | +13.1% | 1,203,135 | 0.0% | 9.52% | -13.5% | |
| SLNO | Soleno | $25,757,000 | +13.1% | 10,302,602 | 0.0% | 5.51% | -13.5% | |
| CRSP | Sell | Crisprnamen akt | $21,684,000 | -43.0% | 259,599 | -50.0% | 4.64% | -56.4% |
| NCNA | New | Nucanaads | $17,233,000 | – | 3,333,333 | +100.0% | 3.69% | – |
| VRNA | Buy | Veronasponds adr | $15,335,000 | +263.3% | 2,457,499 | +172.5% | 3.28% | +178.0% |
| XCUR | Exicure | $12,070,000 | -28.8% | 6,977,000 | 0.0% | 2.58% | -45.5% | |
| SRRA | Sierra Oncology | $9,212,000 | -12.6% | 876,541 | 0.0% | 1.97% | -33.1% | |
| SIEN | Sientra | $8,129,000 | -11.9% | 2,390,843 | 0.0% | 1.74% | -32.6% | |
| PRTK | Paratek | $5,622,000 | +3.7% | 1,041,131 | 0.0% | 1.20% | -20.7% | |
| MTEM | Molecular Templates | $2,180,000 | -21.0% | 200,000 | 0.0% | 0.47% | -39.6% | |
| AGLE | Aeglea | $1,703,000 | -23.3% | 240,500 | 0.0% | 0.36% | -41.4% | |
| CBAY | Cymabay | $947,000 | +107.7% | 131,036 | 0.0% | 0.20% | +59.8% | |
| PRTO | New | Protara | $344,000 | – | 20,610 | +100.0% | 0.07% | – |
| OBSV | Obseva | $218,000 | -57.8% | 87,999 | 0.0% | 0.05% | -67.6% | |
| HSGX | Ocugen | $2,000 | 0.0% | 7,111 | 0.0% | 0.00% | -100.0% | |
| TARA | Exit | Protara | $0 | – | -53,612 | -100.0% | -0.84% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-11-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| SIENTRA INC | 33 | Q4 2022 | 31.2% |
| PARATEK PHARMACEUTICALS INC | 33 | Q4 2022 | 24.9% |
| CYMABAY THERAPEUTICS INC | 30 | Q4 2022 | 8.6% |
| Ocugen | 24 | Q2 2022 | 1.5% |
| Proteon | 22 | Q3 2020 | 18.9% |
| OBSEVA SA | 22 | Q4 2022 | 5.1% |
| Chiasma | 19 | Q1 2020 | 24.6% |
| VERONA PHARMA PLC | 18 | Q4 2022 | 20.9% |
| Sierra Oncology | 18 | Q2 2022 | 23.1% |
| Crispr | 16 | Q3 2020 | 53.6% |
View Abingworth LLP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Verona Pharma plc | August 11, 2022 | 21,313,822 | 4.4% |
| Sierra Oncology, Inc.Sold out | July 11, 2022 | 0 | 0.0% |
| HilleVax, Inc. | May 13, 2022 | 1,838,486 | 5.5% |
| SOLENO THERAPEUTICS INC | April 08, 2022 | 18,368,373 | 15.3% |
| Vera Therapeutics, Inc. | April 07, 2022 | 2,970,156 | 11.1% |
| EXICURE, INC. | February 25, 2022 | 7,084,297 | 6.5% |
| Vaxcyte, Inc. | February 14, 2022 | 4,183,716 | 7.9% |
| Jasper Therapeutics, Inc. | October 04, 2021 | 5,628,558 | 15.4% |
| eFFECTOR Therapeutics, Inc. | September 03, 2021 | 4,822,114 | 11.9% |
| Reneo Pharmaceuticals, Inc. | April 20, 2021 | 1,858,226 | 7.7% |
View Abingworth LLP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-02-12 |
| 13F-NT | 2024-02-02 |
| 13F-NT | 2023-11-03 |
| 4 | 2023-10-02 |
| 13F-NT | 2023-08-04 |
| 4 | 2023-05-10 |
| 13F-NT | 2023-05-05 |
| 13F-HR | 2023-02-10 |
| 4 | 2023-01-31 |
| 13F-HR | 2022-11-10 |
View Abingworth LLP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.